Ocugen signed a binding term sheet to license OCU400 in the Middle East and North Africa, with up to $4M near-term fees and $255M sales milestones plus 22% royalties.
Key Highlights:
- Signed binding term sheet with Roots Pharmaceutical (and Al-Dhow) for exclusive OCU400 rights in MENA.
- Upfront and near-term development payments totaling up to $4 million expected under the license.
- Potential cumulative sales milestones up to $255 million plus 22% royalty on partner net sales.
- Ocugen will manufacture and supply commercial OCU400 under a related supply agreement.
- Definitive agreement expected within 90 days; Phase 3 topline readout for OCU400 due 1Q 2027.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.